Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

LLY's orforglipron study results disappoint, shifting investor focus to Novo Nordisk's bid for first FDA-approved oral ...

Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s Wegovy in the first head-to-head study of the rival medicines.

Shock’ as study reveals how weight-loss pill stacks up against injections - Shares in a pharmaceutical company plummeted ...

FRIDAY, Aug. 8, 2025 (HealthDay News) — A new weight loss pill made by Eli Lilly helped people lose a significant amount of ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications.